Cleared Traditional

K093129 - ILLUMINA VERNCODE GENOTYPING TEST FOR FACOR V AND FACTOR II (FDA 510(k) Clearance)

Class II Pathology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K093129 · Illumina, Inc. · Pathology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2010
Decision
208d
Days
Class 2
Risk

K093129 is an FDA 510(k) clearance for the ILLUMINA VERNCODE GENOTYPING TEST FOR FACOR V AND FACTOR II. Classified as Test, Factor V Leiden Mutations, Genomic Dna Pcr (product code NPQ), Class II - Special Controls.

Submitted by Illumina, Inc. (San Diego, US). The FDA issued a Cleared decision on April 28, 2010 after a review of 208 days - an extended review cycle.

This device falls under the Pathology FDA review panel, regulated under 21 CFR 864.7280 - the FDA pathology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Pathology review framework, consistent with the majority of Class II 510(k) submissions.

View all Illumina, Inc. devices

Submission Details

510(k) Number K093129 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 02, 2009
Decision Date April 28, 2010
Days to Decision 208 days
Submission Type Traditional
Review Panel Pathology (PA)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
131d slower than avg
Panel avg: 77d · This submission: 208d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code NPQ Test, Factor V Leiden Mutations, Genomic Dna Pcr
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7280
Definition In Vitro Diagnostic Test To Detect The Factor V Leiden Mutation In Genomic Dna, As An Aid To Diagnosis In The Evaluation Of Patients With Suspected Thrombophilia.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Pathology devices follow this clearance model.